Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H) oEso-gastric junction and gastric adenocarcinoma: An open-label GERCOR phase II study
Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H) oEso-gastric junction and gastric adenocarcinoma: An open-label GERCOR phase II study
Patologie
Stato
Aperto - reclutamento in corso
Codice studio
DEWI G-123
Codice EudraCT
2023-506102-39-00
Sponsor/Promotore
GERCOR
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator